NSAIDs and COVID-19: A Systematic Review and Meta-analysis.

Published on Aug 2, 2021in Drug Safety3.442
· DOI :10.1007/S40264-021-01089-5
Nicholas Moore65
Estimated H-index: 65
(University of Bordeaux),
Pauline Bosco-Levy7
Estimated H-index: 7
(University of Bordeaux)
+ 2 AuthorsCécile Droz-Perroteau10
Estimated H-index: 10
(University of Bordeaux)
Nonsteroidal anti-inflammatory drugs (NSAIDs) have been discouraged for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, fearing that they could increase the risk of infection or the severity of SARS-CoV-2. Original studies providing information on exposure to NSAIDs and coronavirus disease 2019 (COVID-19) outcomes were retrieved and were included in a descriptive analysis and a meta-analysis with Cochrane Revue Manager (REVMAN 5.4), using inverse variance odds ratio (OR) with random- or fixed-effects models. Of 92,853 papers mentioning COVID-19, 266 mentioned NSAIDs and 61 mentioned ibuprofen; 19 papers had analysable data. Three papers described NSAID exposure and the risk of SARS-CoV-2 positivity, five papers described the risk of hospital admission in positive patients, 10 papers described death, and six papers described severe composite outcomes. Five papers studied exposure to ibuprofen and death. Using random-effects models, there was no excess risk of SARS-CoV-2 positivity (OR 0.86, 95% confidence interval [CI] 0.71–1.05). In SARS-CoV-2-positive patients, exposure to NSAIDs was not associated with excess risk of hospital admission (OR 0.90, 95% CI 0.80–1.17), death (OR 0.88, 95% CI 0.80–0.98), or severe outcomes (OR 1.14, 95% CI 0.90–1.44). With ibuprofen, there was no increased risk of death (OR 0.94, 95% CI 0.78–1.13). Using a fixed-effect model did not modify the results, nor did the sensitivity analyses. The theoretical risks of NSAIDs or ibuprofen in SARS-CoV-2 infection are not confirmed by observational data.
📖 Papers frequently viewed together
2 Citations
#1Aditya Sahai (Cleveland Clinic)H-Index: 2
#2Rohan Bhandari (Cleveland Clinic)H-Index: 3
Last. Scott Cameron (Cleveland Clinic Lerner Research Institute)H-Index: 54
view all 18 authors...
Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 is an ongoing viral pandemic marked by increased risk of thrombotic events. However, the role of platelets in the elevated observed thrombotic risk in COVID-19 and utility of antiplatelet agents in attenuating thrombosis is unknown. We aimed to determine if the antiplatelet effect of aspirin may mitigate risk of myocardial infarction, cerebrovascular accident, and venous thromboembolism in COVID-19. We evaluated 22,072 symptomatic patients...
4 CitationsSource
Summary Background Early in the pandemic it was suggested that pre-existing use of non-steroidal anti-inflammatory drugs (NSAIDs) could lead to increased disease severity in patients with COVID-19. NSAIDs are an important analgesic, particularly in those with rheumatological disease, and are widely available to the general public without prescription. Evidence from community studies, administrative data, and small studies of hospitalised patients suggest NSAIDs are not associated with poorer COV...
9 CitationsSource
#1Joht Singh Chandan (Warw.: University of Warwick)H-Index: 14
#2Dawit T. Zemedikun (University of Birmingham)H-Index: 4
Last. Shamil Haroon (University of Birmingham)H-Index: 11
view all 24 authors...
Objectives To identify whether active use of non-steroidal anti-inflammatory drugs (NSAIDs) increases susceptibility to developing suspected or confirmed COVID-19 compared to the use of other common analgesics. Methods We performed a propensity score-matched cohort study with active comparators using a large UK primary care dataset. The cohort consisted of adult patients aged ≥18 years with a diagnosis of osteoarthritis and followed up from 30th January to 31st July 2020. Patients prescribed an ...
9 CitationsSource
#1Justin T. Reese (LBNL: Lawrence Berkeley National Laboratory)H-Index: 24
#2Ben D ColemanH-Index: 1
Last. Andrew E. Williams (Tufts University)H-Index: 9
view all 22 authors...
BACKGROUND Cyclooxygenase (COX) inhibitors including non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used to reduce pain, fever, and inflammation but have been associated with complications in community acquired pneumonia and other respiratory tract infections (RTIs). Conclusive data are not available about potential beneficial or adverse effects of COX inhibitors on COVID-19 patients. METHODS We conducted a retrospective, multi-center observational study by leveraging the harmonized...
1 CitationsSource
#1Jungchan Park (SMC: Samsung Medical Center)H-Index: 5
#2Seung-Hwa Lee (SMC: Samsung Medical Center)H-Index: 6
Last. Kwangmo Yang (SMC: Samsung Medical Center)H-Index: 2
view all 5 authors...
Non-steroidal anti-inflammatory drugs (NSAIDs) have been widely used in patients with respiratory infection, but their safety in coronavirus disease 19 (Covid-19) patients has not been fully investigated. We evaluated an association between NSAID use and outcomes of Covid-19. This study was a retrospective observational cohort study based on insurance benefit claims sent to the Health Insurance Review and Assessment Service of Korea by May 15, 2020. These claims comprised all Covid-19-tested cas...
4 CitationsSource
#1Ricky Vaja (NIH: National Institutes of Health)H-Index: 6
#2Jeffrey Shi Kai Chan (CUHK: The Chinese University of Hong Kong)H-Index: 8
Last. Jane A. Mitchell (NIH: National Institutes of Health)H-Index: 79
view all 8 authors...
Aims In light of the recent safety concerns relating to NSAID use in COVID-19, we sought to evaluate cardiovascular and respiratory complications in patients taking NSAIDs during acute lower respiratory tract infections. Methods We carried out a systematic review of randomised controlled trials and observational studies. Studies of adult patients with short-term NSAID use during acute lower respiratory tract infections, including bacterial and viral infections, were included. Primary outcome was...
12 CitationsSource
#1Laila Carolina Abu Esba (National Guard Health Affairs)H-Index: 1
#2Rahaf Ali Alqahtani (National Guard Health Affairs)H-Index: 1
Last. Gahdah Mardawi (National Guard Health Affairs)H-Index: 1
view all 6 authors...
Introduction Ibuprofen disappeared from the pharmacy shelves during the 2019 coronavirus (COVID-19) pandemic. However, a while later, information circulated that ibuprofen should be avoided as it could worsen COVID-19 symptoms. The aim of our study was to assess the association of acute and chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) with worse COVID-19 outcomes. Methods We did a prospective cohort study between April 12 and June 1, 2020. Adults consecutively diagnosed with COVI...
19 CitationsSource
#1Peter HorbyH-Index: 67
#3Enti SpataH-Index: 9
view all 35 authors...
Summary Background Azithromycin has been proposed as a treatment for COVID-19 on the basis of its immunomodulatory actions. We aimed to evaluate the safety and efficacy of azithromycin in patients admitted to hospital with COVID-19. Methods In this randomised, controlled, open-label, adaptive platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), several possible treatments were compared with usual care in patients admitted to hospital with COVID-19 in the UK. The trial is underw...
203 CitationsSource
1 CitationsSource
#1Angel Y S Wong (Lond: University of London)H-Index: 21
#2Brian MacKenna (University of Oxford)H-Index: 11
Last. Ben Goldacre (University of Oxford)H-Index: 37
view all 32 authors...
Objectives To assess the association between routinely prescribed non-steroidal anti-inflammatory drugs (NSAIDs) and deaths from COVID-19 using OpenSAFELY, a secure analytical platform. Methods We conducted two cohort studies from 1 March to 14 June 2020. Working on behalf of National Health Service England, we used routine clinical data in England linked to death data. In study 1, we identified people with an NSAID prescription in the last 3 years from the general population. In study 2, we ide...
12 CitationsSource
Cited By1